167 related articles for article (PubMed ID: 18855679)
21. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
22. Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Jacobsen B; Santoni-Rugiu E; Illemann M; Kriegbaum MC; Laerum OD; Ploug M
Int J Cancer; 2012 Jun; 130(11):2734-9. PubMed ID: 21792890
[TBL] [Abstract][Full Text] [Related]
23. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Ploug M
Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
[TBL] [Abstract][Full Text] [Related]
24. Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Magnussen S; Hadler-Olsen E; Latysheva N; Pirila E; Steigen SE; Hanes R; Salo T; Winberg JO; Uhlin-Hansen L; Svineng G
PLoS One; 2014; 9(8):e105929. PubMed ID: 25157856
[TBL] [Abstract][Full Text] [Related]
25. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
26. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression.
Wilhelm OG; Wilhelm S; Escott GM; Lutz V; Magdolen V; Schmitt M; Rifkin DB; Wilson EL; Graeff H; Brunner G
J Cell Physiol; 1999 Aug; 180(2):225-35. PubMed ID: 10395292
[TBL] [Abstract][Full Text] [Related]
27. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.
Kriegbaum MC; Persson M; Haldager L; Alpízar-Alpízar W; Jacobsen B; Gårdsvoll H; Kjær A; Ploug M
Curr Drug Targets; 2011 Nov; 12(12):1711-28. PubMed ID: 21707479
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
30. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Shi Z; Stack MS
Biochem J; 2007 Oct; 407(2):153-9. PubMed ID: 17880283
[TBL] [Abstract][Full Text] [Related]
31. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
32. The urokinase receptor in the central nervous system.
Archinti M; Britto M; Eden G; Furlan F; Murphy R; Degryse B
CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):271-94. PubMed ID: 20874700
[TBL] [Abstract][Full Text] [Related]
33. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
34. The urokinase receptor interactome.
Eden G; Archinti M; Furlan F; Murphy R; Degryse B
Curr Pharm Des; 2011; 17(19):1874-89. PubMed ID: 21711237
[TBL] [Abstract][Full Text] [Related]
35. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
36. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
[TBL] [Abstract][Full Text] [Related]
37. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes.
García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M
Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
39. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
40. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
